Immunome Q3 2022 Earnings Report
Key Takeaways
Immunome reported its Q3 2022 financial results and provided a corporate update, focusing on the clinical trial for IMM-BCP-01 and the expansion of its oncology portfolio.
Completing clinical trial for IMM-BCP-01, its COVID-19 antibody program.
Continuing to expand oncology portfolio including planned submission of the IND for IMM-ONC-01 by mid 2023.
Monitoring the evolution of multiple new variants of SARS-CoV-2, including BA.4.6, BQ.1, BQ.1.1 and BF.7.
Anticipating obtaining topline safety and PK data by the end of the year and look forward to announcing those results in the beginning of 2023.
Immunome
Immunome
Forward Guidance
Immunome is focused on advancing its platform and programs, executing its regulatory, research, clinical and strategic plans, and achieving anticipated upcoming milestones.
Positive Outlook
- Advancement of its platform and programs
- Execution of its regulatory plans
- Execution of research plans
- Execution of clinical plans
- Execution of strategic plans
Challenges Ahead
- Impact of the COVID-19 pandemic on Immunome’s business
- Research and development data are subject to differing interpretations and assessments
- Ability to execute on its strategy, including with respect to its R&D efforts, IND submissions and other regulatory filings
- Effectiveness of Immunome’s product candidates, including the possibility that further preclinical data and any clinical trial data may be inconsistent with the data used for advancing the product candidates and that further variants of concern could emerge
- Ability to fund operations and raise capital